Novonesis Reports 7% Organic Sales Growth in 2025, Eyes Margin Expansion in 2026
Event summary
- Novonesis achieved 7% organic sales growth in 2025, with adjusted EBITDA margin at 37.1%.
- Food & Health segment grew 8%, while Planetary Health saw 6% growth, including double-digit growth in Energy.
- Emerging Markets grew 9% organically, outpacing Developed Markets at 6%.
- Adjusted net profit increased by 17%, with free cash flow before acquisitions at EUR 770.4 million.
- 2026 outlook projects 5-7% organic sales growth and adjusted EBITDA margin between 37-38%.
The big picture
Novonesis' strong 2025 performance underscores its position as a leader in biosolutions, combining innovation with scale. The company's focus on margin expansion and strategic exits reflects broader industry trends toward operational efficiency and market consolidation. With a clear path to its 2030 targets, Novonesis is positioning itself for long-term resilience in a competitive landscape.
What we're watching
- Growth Sustainability
- Whether Novonesis can maintain its broad-based growth across segments amid potential lower consumer sentiment in 2026.
- Margin Expansion
- The pace at which Novonesis can expand its adjusted EBITDA margin despite currency headwinds.
- Execution Risk
- How the company's strategy to exit certain countries will impact its overall growth and profitability.
Related topics